Dechra Pharmaceuticals PLC Exercise of LTIP options (4797Q)

TIDMDPH

RNS Number : 4797Q

Dechra Pharmaceuticals PLC

29 November 2016

29 November 2016

Dechra(R) Pharmaceuticals PLC

(Dechra or the Company)

Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them (PCA)

Exercise of LTIP options:

Dechra Pharmaceuticals PLC announces that on 28 November 2016, the following PDMRs exercised nil cost options over ordinary shares of 1p each in the Company. The options were granted to them on 27 November 2013 pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP). The exercise of the options was subject to the achievement of performance conditions which vested at 96.25% of the total award. The PDMRs named below received in satisfaction of the vesting of their awards under the LTIP the number of ordinary shares set out below:

 
 Name        Capacity    Options Exercised   Total beneficial     Percentage 
                                              shareholding         of issued 
                                              following            share 
                                              this announcement    capital 
 Ian Page    Director    124,375             876,541              0.942% 
 Tony 
  Griffin    Director    32,849               84,953              0.091% 
 

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

 
 1.   Details of the Person Discharging Managerial 
       Responsibility ("PDMR")/person closely 
       associated with them ("PCA") 
---  ---------------------------------------------------------------- 
 a)   Name                           Ian Page 
---  -----------------------------  --------------------------------- 
 2.   Reason for the notification 
---  ---------------------------------------------------------------- 
 a)   Position/status                Director 
---  -----------------------------  --------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
---  -----------------------------  --------------------------------- 
 3.   Details of the Issuer 
---  ---------------------------------------------------------------- 
 a)   Name                           Dechra Pharmaceuticals PLC 
---  -----------------------------  --------------------------------- 
 b)   LEI code                       N/A 
---  -----------------------------  --------------------------------- 
 4.   Details of the transaction(s): section 
       to be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ---------------------------------------------------------------- 
 a)   Description                    Ordinary Shares of 1 pence 
       of the financial               each 
       instrument 
 
       Identification                 ISIN: GB0009633180 
       code 
---  -----------------------------  --------------------------------- 
 b)   Nature of                      Exercise of nil cost options 
       the transaction                under the Company's Long Term 
                                      Incentive Plan 
---  -----------------------------  --------------------------------- 
 c)   Price(s) and                   Price(s)          Volume(s) 
       volumes(s) 
                                      Nil cost          124,375 
---  -----------------------------  ----------------  --------------- 
 d)        Aggregated 
            information 
             *    Aggregate volume     N/A 
 
 
             *    Price 
---  -----------------------------  --------------------------------- 
 e)   Date of the                    2016.11.28 
       transaction 
---  -----------------------------  --------------------------------- 
 f)   Place of the                   Outside a trading venue 
       transaction 
---  -----------------------------  --------------------------------- 
 
 
 1.   Details of the Person Discharging Managerial 
       Responsibility ("PDMR")/person closely 
       associated with them ("PCA") 
---  ---------------------------------------------------------------- 
 a)   Name                           Tony Griffin 
---  -----------------------------  --------------------------------- 
 2.   Reason for the notification 
---  ---------------------------------------------------------------- 
 a)   Position/status                Director 
---  -----------------------------  --------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
---  -----------------------------  --------------------------------- 
 3.   Details of the Issuer 
---  ---------------------------------------------------------------- 
 a)   Name                           Dechra Pharmaceuticals PLC 
---  -----------------------------  --------------------------------- 
 b)   LEI code                       N/A 
---  -----------------------------  --------------------------------- 
 4.   Details of the transaction(s): section 
       to be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ---------------------------------------------------------------- 
 a)   Description                    Ordinary Shares of 1 pence 
       of the financial               each 
       instrument 
 
       Identification                 ISIN: GB009633180 
       code 
---  -----------------------------  --------------------------------- 
 b)   Nature of                      Exercise of nil cost options 
       the transaction                under the Company's Long Term 
                                      Incentive Plan 
---  -----------------------------  --------------------------------- 
 c)   Price(s) and                   Price(s)          Volume(s) 
       volumes(s) 
                                      Nil cost          32,849 
---  -----------------------------  ----------------  --------------- 
 d)        Aggregated 
            information 
             *    Aggregate volume     N/A 
 
 
             *    Price 
---  -----------------------------  --------------------------------- 
 e)   Date of the                    2016.11.28 
       transaction 
---  -----------------------------  --------------------------------- 
 f)   Place of the                   Outside a trading venue 
       transaction 
---  -----------------------------  --------------------------------- 
 

For further information, please contact:

Suzana Cross, General Counsel and Company Secretary

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBLBPTMBMTBLF

(END) Dow Jones Newswires

November 29, 2016 13:10 ET (18:10 GMT)